Last Price
0.082
Today's Change
-0.003 (3.52%)
Day's Change
0.082 - 0.086
Trading Volume
14,840,107
Market Cap
600 Million
Shares Outstanding
7 Billion
Avg Volume
16,458,710
Avg Price (50 Days)
0.10
Avg Price (200 Days)
0.09
PE Ratio
-8.20
EPS
-0.01
Earnings Announcement
28-Feb-2024
Previous Close
0.09
Open
0.09
Day's Range
0.082 - 0.086
Year Range
0.039 - 0.15
Trading Volume
14,840,107
1 Day Change
-3.53%
5 Day Change
0.00%
1 Month Change
-21.90%
3 Month Change
-18.00%
6 Month Change
70.83%
Ytd Change
-25.45%
1 Year Change
-34.40%
3 Year Change
-60.00%
5 Year Change
382.35%
10 Year Change
727.45%
Max Change
-99.43%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.